Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.
Description: Death due to any cause
Measure: All-cause mortality Time: 30 daysDescription: Death due to any cause
Measure: All-cause mortality Time: 1 yearDescription: Death due to liver-related cause
Measure: Liver-related mortality Time: 28 daysDescription: Death due to liver-related cause
Measure: Liver-related mortality Time: 1 yearDescription: Patients will be assessed for this outcome for up to 1 year
Measure: Overall survival Time: Up to 1 yearDescription: Onset of hepatic decompensation due to COVID-19 disease; patients will be assessed for this outcome for up to 1 year
Measure: Number of patients with hepatic decompensation Time: Up to 1 yearDescription: Patients will be assessed for this outcome for up to 1 year.
Measure: Number of patients requiring hospitalization Time: Up to 1 yearDescription: Patients will be assessed for this outcome for up to 1 year.
Measure: Duration of hospitalization Time: Up to 1 yearDescription: Patients will be assessed for this outcome for up to 1 year.
Measure: Length of intensive care unit (ICU) stay Time: Up to 1 yearDescription: Patients will be assessed for this outcome for up to 1 year.
Measure: Number of participants requiring mechanical ventilation Time: Up to 1 year